Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

NCT01388621 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Panitumumab
DRUG: pegylated liposomal doxorubicin (PLD)
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Panitumumab

Sponsor

WiSP Wissenschaftlicher Service Pharma GmbH

Collaborators

[object Object]